Clinical Trial Search

Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Post Surgical Ocular Inflammation and Pain

Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105

Kala Pharmaceuticals, Inc. Results Apr 2019 0.6% serious AE View details

Phase 3 N=120 Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

Psoriasis

Primary: proSPI (s) at Week 16 Compared to Baseline — 24.89; 2.34 scores on a scale — p=<0.0001

Novartis Pharmaceuticals Results Apr 2019 10.8% serious AE View details

Phase 3 N=348 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis

Primary: Harvey Bradshaw Index — 3.7; 3.2; 4.2 units on a scale

University of Maryland, Baltimore Results Apr 2019 0.0% serious AE View details

Phase 3 N=571 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

Ovarian Cancer

Primary: Progression-free Survival — 20.4; 23.2 percentage of participants

Gynecologic Oncology Group Results Apr 2019 2.2% serious AE View details

Phase 3 N=252 Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function

Pulmonary Function; Newborn, Abnormal · Infant Wheeze · In-utero Nicotine

Primary: Forced Expiratory Flow at 75% of Expired Volume (FEF75) — 188.7; 200.7 ml/s — p=0.19

Oregon Health and Science University Results Apr 2019 23.1% serious AE View details

Phase 3 N=414 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

Primary: Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24 — 58; 67; 22 Participants

Novartis Pharmaceuticals Results Apr 2019 15.7% serious AE View details

Phase 3 N=300 A Safety and Immunogenicity Study of IVACFLU-A/H5N1

Avian Influenza

Primary: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40 — 0; 0; 0; 0 Participants

Institute of Vaccines and Medical Biologicals… Results Apr 2019 1.4% serious AE View details

Phase 3 N=119 Alternatives for Reducing Chorea in Huntington Disease

Chorea Associated With Huntington Disease

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…

Auspex Pharmaceuticals, Inc. Results Apr 2019 26.9% serious AE View details

Phase 3 N=595 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non - Small Cell Lung Cancer NSCLC

Primary: Overall Survival (OS) — 11.7; 6.8; 11.5; 8.7 months — p=0.109

AstraZeneca Results Apr 2019 32.7% serious AE View details

Phase 3 N=115 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Prostate Cancer

Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318

Takeda Results Apr 2019 6.1% serious AE View details

Phase 3 N=229 A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia · Small-Cell Lymphoma

Primary: Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30 — 78.5; 31.1…

Pharmacyclics LLC. Results Apr 2019 48.3% serious AE View details

Phase 3 N=243 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

Carcinoma, Squamous Cell of Head and Neck

Primary: Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC) — 5.5; 4.2 months

Merck KGaA, Darmstadt, Germany Results Apr 2019 28.0% serious AE View details

Phase 3 N=86 Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Anesthesia, General

Primary: Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.9 in Participants With or Having a Past History of Pulmonary Disease — 2.42; 2.1 Minutes

Merck Sharp & Dohme LLC Results Apr 2019 9.1% serious AE View details

Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess

Iatrogenic Cushing Disease

Primary: CT Abdomen — 0.08; -0.03 ratio

Barts & The London NHS Trust Results Apr 2019 18.9% serious AE View details

Phase 3 N=151 The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Primary: Overall Adverse Event Summary — 67; 55; 23; 22 Participants

AstraZeneca Results Apr 2019 6.6% serious AE View details